Floragraph Presents at Translational Microbiome Conference in Boston April 17, 2019
San Jose, February 10, 2019 – Floragraph, Inc., developer of novel microbiome analysis technology, announced today that founder & CEO Alicia Scheffer-Wong has been invited to present at the 5th annual Translational Microbiome Conference, to be held April 16-18 in Boston.
The presentation details are as follows:
Title: A Targeted, Point of Care Solution for Microbiome Analysis
Date: Wednesday, April 17, 2019
Session: Main Track
Venue: Westin Copley Place, Boston MA
“It’s a privilege to be invited to share our latest data with our peers in the microbiome field,” said Scheffer-Wong. Her talk will provide an introduction to Floragraph’s novel microfluidic sample preparation methodology and innovative microarray measurement technology, as well as experimental data. Scheffer-Wong will show data characterizing the performance of Floragraph’s sample prep solution, describing their novel genome-wide design strategy for species-specific microarray probes along with preliminary data, and current progress toward generating rationally-selected candidate biomarker pools for functional microbiome analysis.
Floragraph is an early stage molecular tools startup developing the first point-of-care microbiome profiling device. Based in Sunnyvale, CA, their technology targets “doodoo-to-data” in hours instead of weeks, at low cost. The Floragraph platform provides sensitive quantitation of rationally selected candidate “microbiomarkers”, accelerating the translation of R&D to applied settings. They company’s initial focus is exploring diagnostic utility of infant microbiome analysis. Working with collaborators, they are developing panels of candidate microbiome biomarkers for neonatal sepsis, anemia and failure to thrive in the neonatal intensive care unit.
About the Conference:
As the official conference of The Microbiome Coalition (TMBC), the Arrowhead Translational Microbiome Conference was the first microbiome conference in the field to focus exclusively on the hurdles and challenges to commercial success in the space.
The conferences brings together the leading microbiome companies working to successfully commercialize microbiome-based diagnostics, therapeutics, adjunct therapies and direct-to-consumer services and products across a range of therapeutic areas, from gut to skin and beyond. Expanding on this core focus year on year, we continue to offer informative, hands-on workshops, panels sponsored and directed by industry to focus on your concerns and tightly curated content that goes beyond the usual infomercials to provide tangible and useful insights to how your peers are addressing their commercial approach to the space.
Entering its 5th year in 2019, the meeting will continue to focus and build on the challenges and hurdles that companies working in the microbiome space will have to recognize and navigate in order to successfully commercialize their products. With a broad focus spanning multiple disease states (oncology, dermatology, inflammatory disorders, among others) attendees will have the opportunity to hear the leading companies discuss the work they have underway and how they are meeting these challenges head-on to apply recent discoveries to a variety of disease processes, restoration of health and improved outcomes.
1230 Bordeaux Dr.
Sunnyvale, CA 94089
Alicia Scheffer-Wong, Founder & CEO